araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Could the Stroke Volume Variation Predict a Fluid Responsiveness in Thoracotomy?

Summary: There are some risks of pulmonary edema in patients undergoing pulmonary lobectomy with one lung ventilation. The overloading of fluid administration could be related to the development of pulmonary edema in patents after thoracic surgery. But fluid restriction may cause major organ hypoperfusion during the surgery. The purpose of this study is to evaluate the ability of stroke volume variation as an indicator for a fluid responsiveness in patient who receives pulmonary lobectomy via thoracotomy.

Detailed description: Perioperative fluid management during thoracic surgery is a significantly important, because it is quite difficult to prevent pulmonary edema due to the fluid overload and compromise perfusion of vital organ. So, it is essential to maintain optimal organ perfusion by appropriate fluid management during thoracic surgery. Stroke volume variation (SVV) is derived from pulse contour analysis and it is known that SVV ≥12~15% correlate with fluid responsiveness, defined as a significant increase in cardiac output with fluid loading, dung two-lung ventilation. It is a parameter derived from changes in stroke volume (SV) that is according to the heart-lung interaction during mechanical ventilation. positive pressure ventilation induces cyclic changes in left ventricular SV that are related mainly to the expiratory decrease in right ventricular filling and ejection. This is a reflected by variations in the SV. However both ventilator issues, such as tidal volume, PEEP, chest and lung condition, and the cardiovascular condition, such as heart rate, rhythm, ventricular function, cardiac afterload, arterial compliance may affect SVV. Recently some studies reported that SVV could predict fluid responsiveness in mechanically ventilated patients under various conditions. But it is still unclear whether SVV could predict fluid responsiveness during one lung ventilation with the chest open via a thoracotomy. During one-lung ventilation, the shunted blood flow through the non-ventilated-lung dose not contribute to the generation of SVV. And with the chest opening by thoracotomy, the pressure generated by ventilator would not be transmitted to the pulmonary vessels but rather to the atmosphere. So, the purpose of this study is to evaluate the ability of SVV as an indicator a fluid responsiveness particularly in patients undergoing one-lung ventilation with thoracotomy and to found the optimal threshold value of SVV for fluid management during thoracic surgery.

Eligibility: Inclusion Criteria:
  -  The patients scheduled for pulmonary lobectomy with one lung ventilation by lung cancer, nodule, or pulmonary tuberculosis under thoracoscopy or thoracotomy in our hospital
  Exclusion Criteria:
  -  The patients with known cardiac disease include arrythmia
  -  American society of anesthesia physical status III, IV, V

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: The Lira Pump Trial

Summary: A randomized placebo-controlled clinical trial investigating the effects of Liraglutide as an add-on to intensive insulin therapy in overweight insulin pump treated type 1 diabetes patients in suboptimal glycemic control.


Eligibility: Inclusion Criteria:
  -  Type 1 diabetes ≥ 1 year
  -  BMI > 25 kg/m2
  -  Insulin pump ≥ 1 year
  -  HbA1c > 58 mmol/mol
  -  Use of carbohydrate counting and the insulin pump bolus calculator
  Exclusion Criteria:
  -  Gastroparesis
  -  Impaired renal function (eGFR < 60 ml/min/1.73m2)
  -  Liver disease with ALAT > 2.5 times the upper limit of the reference interval
  -  Acute or chronic pancreatitis or history of chronic pancreatitis or idiopathic acute pancreatitis
  -  Inflammatory bowel disease
  -  History of cancer (except basal cell skin cancer) which in the investigators opinion could interfere with the results of the trial, or cancer during the past 5 years
  -  Thyroid adenoma
  -  Subjects with personal or family history of MTC or MEN2
  -  Use of anti-diabetic medicine (other than insulin), corticosteroids or other drugs affecting glucose metabolism during the study period or within 30 days prior to study start
  -  Known or suspected alcohol or drug abuse
  -  Other concomitant medical or psychological condition that according to the investigator's assessment makes the patient unsuitable for study participation
  -  Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods.
  -  Simultaneous participation in any other clinical intervention trial
  -  Known or suspected hypersensitivity to Liraglutide
  -  Inability to understand the patient information and to give informed consent
  -  Acute treatment required proliferative retinopathy or maculopathy (macular oedema)
  -  Any Cardiac disorder which in the investigators opinion could interfere with the safety and results of the trial.

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Characterization of Methylation Patterns in Lung Cancer

Summary: In this study the investigators will collect Blood,sputum and saliva samples for Characterization of Methylation Patterns in lung Cancer.

Detailed description: Lots of information about the relationship between changes in methylation patterns and various diseases are accumulated in recent years. Characterization of methylation changes that occur in cancer may contribute to the development of methods for early detection of cancer by detecting cancer cells in liquids. Early detection of such changes and their correlation examining different cancers may lead to a diagnostic tool for the early detection of cancers and improve the treatment of these patients. Detection by molecular analysis can be a sensitive method and non-invasive early diagnosis of the disease In this study the investigators will collect Blood,sputum and saliva samples for Characterization of Methylation Patterns in lung Cancer.

Eligibility: Inclusion Criteria:
  -  Patients with suspected lung tumor
  Exclusion Criteria:
  -  Patients who have active disease other than lung cancer during the sample collecting

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer

Summary: This is a single center study to assess the efficacy of CyPath® Early Detection Lung Cancer Assay to detect lung cancer cells from deep lung sputum.

Detailed description: Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) is a porphyrin that can label cancer cells by reacting to the increased number of low-density lipoproteins coating the surface of cancer cells and the porous nature of the cancer cell membrane, causing the cell to fluoresce under specific wavelengths of light. The primary objective of this clinical trial is to determine the the presence or absence of red fluorescent [ie, cancer] cells (RFCs) from deep-lung sputum samples using the CyPath® Early Lung Cancer Detection Assay from one cohort of Participants who are healthy. The results from this trial will be compared with two additional cohorts of Participants including individuals at high risk for lung cancer and individuals diagnosed with lung cancer. Collection of the sputum samples from high-risk individuals and lung cancer patients is complete (NCT00894127).
  Participants who satisfy the inclusion/exclusion criteria will be enrolled into the study and assigned to the healthy cohort. The sputum samples will be collected at the study site or at the Participant's home after explanation of the collection procedure by study staff. Samples will be identified with an identification number blinding the sample identity. Each subject's sputum specimen will be processed onto 13 microscope slides at the University of Texas Health Science Center of San Antonio (UTHSCSA) Laboratory. The UTHSCSA laboratory will process each sputum sample onto slides using the ThinPrep T2000 processor for use in the CyPath® Early Lung Cancer Detection Assay.
  Twelve slides from each sputum sample will be labeled with CyPath®. One slide will be used to preform PAP staining for the presence of macrophages. Macrophages are an indication that the sputum sample is from deep within the lungs. A cytopathologist will review the slide and record results on a specimen adequacy form. bioAffinity researchers who will be blinded as to the Participant's identity will perform the CyPath® labeling and scoring of the slides. The study results of the healthy cohort will be used for comparison with the results of a closed study in which the sputum from individuals at high risk of lung cancer and individuals diagnosed with lung cancer was compared.
  Findings of the CyPath® assay will not be used in the diagnosis or treatment of Participants.

Eligibility: Inclusion Criteria:
  -  Participants who have never smoked nor have known lung diseases
  Exclusion Criteria:
  -  Severe obstructive lung disease
  -  Angina with minimal exertion
  -  Pregnancy
  -  Have or have had cancer other than lung cancer
  -  Worked in the mining Industry

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: The Prognostic and Predictive Value of the CA-125 Marker in Lung Cancer Monitoring

Summary: The tumor associated CA-125antigen for diagnosis and follow-up of ovarian cancer was well defined. Increased serum CA125 level may have many diagnoses other than ovarian cancer, including breast, colorectal and lung cancer. 80% lung cancer patients were diagnosed at advanced stage. Malignant pleural effusion secondary to lung cancer represented the condition of cancer cell involved pleura.
  The CA-125 level may reflect the extent of tumor involved in pleura (tumor burden), it could be correlated with the prognosis. This study was performed to examine the properties of CA-125 by measuring pleural and blood CA-125 levels in lung cancer with or without malignant pleural effusion; meanwhile to examine whether the rate of decline in CA 125 during primary therapy as a surrogate indicator for survival.


Eligibility: Inclusion Criteria:
  -  Histologically proved lung cancer
  Exclusion Criteria:
  -  History of other cancers within the past 5 years
  -  Pregnancy or breast milk feeding
  -  TB pleuritis and peritonitis

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients

Summary: This is an open label expanded access protocol for the treatment of up to approximately 40 adult or pediatric (defined as age <18 years) patients with tumors harboring either a chromosomal translocation or activating mutation involving the ALK or ROS1 gene or an activating genetic alteration involving the cMET gene who cannot swallow the crizotinib capsule but may be able to derive benefit from treatment with an alternative oral formulation of crizotinib.

Detailed description: Crizotinib is indicated in the U.S. for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. Commercially available dosage forms are 250 mg and 200 mg capsules. This expanded access protocol (EAP) is designed to provide access to an alternative oral formulation of crizotinib for those patients who are unable to swallow capsules.

Eligibility: Inclusion Criteria:
  -  Histologically or cytologically proven diagnosis of a primary or metastatic malignancy that is positive for a chromosomal translocation or activating mutation involving the ALK or ROS1 gene or an activating genetic alteration involving the c MET gene, as determined by local clinical testing that is appropriately validated in accordance with applicable regulatory guidelines and/or practice standards (patients with tumors harbouring other genetic alterations that may potentially benefit from treatment with crizotinib eg NTRK3 ETV6 fusion gene may be considered on a case by case basis subject to approval by the sponsor).
  -  Inability to swallow crizotinib capsules, adult patients of whom must either have a feeding tube in place or have completed clinical evaluation of dysphagia without any reversible causes identified.
  -  At least 12 months of age (patients <12 months of age will be evaluated on a case by case basis and discussed with the sponsor).
  Exclusion Criteria:
  -  Currently receiving crizotinib, another ALK inhibitor, or an investigational product.
  -  Adult patients who have been previously treated with crizotinib.

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)

Summary: The purpose of this study is to determine the recommended dose of the sustained-release form of BPS (TRK-100STP low dose or high dose) in Japanese patients with CRF (Primary glomerular disease/nephrosclerosis).


Eligibility: Inclusion Criteria:
  -  The CRF patient with primary glomerular disease or nephrosclerosis as the primary disease
  -  The patient with progressive CRF
  Exclusion Criteria:
  -  The patient with secondary glomerular disease
  -  The patient with CRF caused by pyelonephritis, interstitial/tubular nephritis, gouty kidney, polycystic kidney disease, or nephroureterolithiasis

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung

Summary: The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of HM61713 in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).

Detailed description: This is a single-arm, open-label, Phase 2 study to assess the anti-tumor efficacy of oral single agent HM61713 administered to patients with T790M-positive NSCLC after treatment with an EGFR-TKI as measured by objective response rate (ORR).

Eligibility: Inclusion Criteria:
  -  Age: at least 20 years of age
  -  Cytologically or histologically confirmed adenocarcinoma of locally advanced or metastatic NSCLC which is not amenable to curative surgery or radiotherapy
  -  Radiologically confirmed disease progression after at least one line of treatment with an EGFR-TKI
  -  At least one documented EGFR mutation which is known to be related with susceptibility to EGFR-TKIs (including G719X, exon 19 deletion, L858R, and L861Q)
  -  World Health Organization (WHO) performance score of 0 to 1 with life expectancy of at least 3 months
  -  Centrally confirmed T790M mutation positive tumor status from a tumor sample taken after confirmation of disease progression on the most recent anticancer treatment regimen
  -  At least one lesion (excluding the brain), not previously irradiated that can be accurately measured per RECIST version 1.1
  -  Adequate hematological and biological function
  -  Females of child-bearing potential must agree to use adequate contraception and for 3 months after the last dose of study drug
  -  Male patients should be documented to be sterile or agree to use barrier contraception
  -  Recovery to ≤ Grade 1 or baseline of any toxicities, except for stable sensory neuropathy ≤ Grade 2 and alopecia
  Exclusion Criteria:
  -  Known history of hypersensitivity to active or inactive excipients of HM61713 or drugs with a similar chemical structure of HM61713
  -  Previous treatment with anticancer therapies, EGFR-TKI, HM61713, or other drugs that target T790M-positive mutant EGFR with sparing of wild-type, investigational agent(s) within 28 days prior to the first administration of study drug, radiotherapy
  -  Any non-study related significant surgical procedures within the past 28 days prior to the first administration of study drug
  -  Spinal cord compression, leptomeningeal carcinomatosis or active symptomatic brain metastases
  -  History of any other malignancy
  -  Clinically significant uncontrolled condition(s)
  -  Active or chronic pancreatitis
  -  Anyone with cardiac abnormalities or history
  -  Presence or history of ILD, drug-induced ILD, or presence of radiation pneumonitis
  -  Pregnant or breast feeding
  -  In the opinion of the investigator, the patient is an unsuitable candidate to receive HM61713

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Functional Status in Patients Undergoing Curative Treatment for Lung Cancer

Summary: This trial investigates the impact of curative lung cancer treatment on functional status and exercise tolerance. Furthermore this trial investigates possible underlying causes and consequences of deconditioning.

Detailed description: Preliminary evidence suggests that patients with lung cancer experience a decrease of exercise tolerance and muscle strength during the course of their treatment. The underlying mechanisms and impact of this change has not yet been investigated. In light of this, our trial will prospectively follow a convenience sample of 70 patients with lung cancer who are treated curatively. Patients will be assessed before, during and at the end of the treatment (surgery and/or chemotherapy and/or radiotherapy). The aims of the study are to
  1. Investigate the influence of curative treatment for lung cancer on functional and maximal exercise tolerance (primary outcome).
  2. Investigate the metabolic changes underlying changes in exercise tolerance during curative treatment for lung cancer (primary outcome).
  3. Investigate the relationship between changes in exercise tolerance, daily physical activity, pulmonary function and skeletal muscle function during curative treatment for lung cancer (secondary outcome).
  4. Investigate the relationship between changes in exercise tolerance and self-reported quality of life, functional status, feelings of anxiety and depression and symptoms during curative treatment for lung cancer (secondary outcome).
  5. Investigate the relationship between physical activity and exercise tolerance on one hand and comorbidities, hospitalisations and cancer-related and all-cause mortality on the other hand after curative treatment for lung cancer (exploratory outcome).

Eligibility: Inclusion Criteria:
  -  curative treatment for lung cancer
  Exclusion Criteria:
  -  presence of other neoplasms
  -  progressive neuromuscular and neurological diseases
  -  unstable cardiac disease
  -  pulmonary hypertension
  -  interstitial lung disease
  -  orthopedic conditions that significantly impair functional status
  -  mental or psychiatric disorders that impair the ability to comply with study procedures.
  -  a history of cerebrovascular accident with remaining functional consequences
  -  a history of lung cancer
  -  lack of knowledge of the Dutch, French or English language will be excluded

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: The Prevalence of Lung Cancer in Patients With Interstitial Lung Disease

Summary: The investigators will evaluate the prevalence of lung cancer associated with interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) utilizing the Korean Health Insurance Review and Assessment Service (HIRA) database, spanning the period from January 2011 to December 2011. The database (HIRA-NPS-2011-0001) was based on random sampling of outpatients from whole population. Patients with ILDs, IPF, connective tissue disorder (CTD), and COPD were identified based on the International Classification of Disease-10 (ICD-10) diagnostic codes.

Detailed description: The epidemiology of lung cancer related to interstitial lung disease (ILD) with or without with connective tissue disease (CTD) as well as idiopathic pulmonary fibrosis (IPF) has not been well established yet. Interstitial lung disease has a potential to develop lung cancer in the name of scar cancer. The investigators aimed to explore prevalence of lung cancer in patients with ILD with or without CTD and IPF in comparison with chronic obstructive pulmonary disorder (COPD).
  The investigators will evaluate the prevalence of lung cancer associated with ILD and IPF utilizing the Korean Health Insurance Review and Assessment Service (HIRA) database, spanning the period from January 2011 to December 2011. The database (HIRA-NPS-2011-0001) was based on random sampling of outpatients from whole population. The sample cases are total 1,375,842. Among them 670,258 cases (age > 40) were evaluated. Patients with ILDs, IPF, CTD, and COPD will be identified based on the International Classification of Disease-10 (ICD-10) diagnostic codes.

Eligibility: Inclusion Criteria:
  -  equal to above 40 years old
  Exclusion Criteria:

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Diabetes Risk Reduction Through Eat, Walk, Sleep and Medication Therapy Management for Depressed Cambodians

Summary: The primary aim of the study is to compare the effect of three different interventions on lifestyle risk factors and biological risk factors for type 2 diabetes in depressed Cambodians. The three different interventions are lifestyle, lifestyle plus medication therapy management, and enhanced standard care.

Detailed description: Cambodian Americans have high risk for major depressive disorder and for type 2 diabetes. Depression is a known risk factor for diabetes. Some antidepressants can also increase risk of depression by causing weight gain. DREAM will test the effect of lifestyle and medication therapy management (MTM) on diabetes risk among depressed Cambodian Americans. Community health workers (CHWs) will deliver the lifestyle intervention and assist pharmacists with MTM. Lifestyle and biological risk factors for diabetes, such as depressive symptoms and insulin sensitivity, will be measured before and after the interventions.

Eligibility: Inclusion Criteria:
  -  Self-identified as Cambodian or Cambodian-American
  -  Khmer speaking
  -  Major depressive disorder
  -  Elevated diabetes risk score per ADA guidelines
  -  >= 3 medications
  -  Ambulatory
  -  Competent to give consent.
  Exclusion Criteria:
  -  Pregnancy or plans to become pregnant in the next 2 years
  -  Previous diagnosis of diabetes
  -  Vision or hearing problems that would prevent participation in group sessions
  -  Currently being followed by a physician for major medical problem
  -  Currently being followed by a healthcare provider for major psychiatric problem other than depression

Relevance to patient case: not relevant